Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (301)	8/6/2003 3:37:21 PM
From: Ian@SI	Read Replies (1) \| Respond to of 824

Madharry, I was under the impression that the trial was over (in the sense that enrolment has stopped; and that at least 30 days have elapsed since the last patient was enrolled, but we haven't yet reached the 180 day mark for all of them. Latter milestone will be reached soon enough to be analysed and presented at AHA mid November. if i were getting cabg and a valve operation i would want to be given this drug. I'd want Pex for either CABG alone or both CABG and valve. It prevents deaths - just not more than 30% of the expected CABG deaths at 30 days. I suspect that would be the choice of any informed patient. Ian